Table 1.
Baseline characteristics of patients
| COVID- (n = 176) | COVID+ (n = 40) | p value | Test | |
|---|---|---|---|---|
| Sex, men, n (%) | 111 (63) | 25 (62) | 0.95 | χ2 |
| Age, mean (SD) | 68.1 (±14.4) | 64.8 (±13.5) | 0.17 | Welch |
| Medical history, n (%) | ||||
| Diabetes mellitus | 42 (24) | 12 (30) | 0.42 | χ2 |
| Hyperlipidemia | 57 (32) | 14 (35) | 0.75 | χ2 |
| Atrial fibrillation | 23 (13) | 6 (15) | 0.75 | χ2 |
| Hypertension | 101 (58) | 22 (58) | 0.98 | χ2 |
| Obesity | 17 (13) | 9 (36) | <0.01 | Fischer |
| History of TE | 24 (14) | 6 (15) | 0.82 | χ2 |
| History of stroke or TIA | 31 (18) | 8 (20) | 0.72 | χ2 |
| Treatment at admission, n (%) | ||||
| Antiplatelet therapy | 60 (34) | 11 (28) | 0.42 | χ2 |
| Anticoagulant | 17 (9.7) | 6 (15) | 0.39 | Fischer |
| ARA-2 | 42 (24) | 4 (10) | 0.053 | χ2 |
| ACE inhibitors | 23 (13) | 12 (30) | <0.01 | χ2 |
| Laboratory results | ||||
| CRP, mean (range), mg/L | 20.1 (0–362) | 51.6 (1–263) | <0.01 | Welch |
| Leukocytes, mean (range), g/L | 8,798 (1,265–23,900) | 9,640 (3,000–37,380) | 0.35 | Welch |
| Platelets, mean (range), g/L | 251 (98–494) | 358 (83–755) | <0.001 | Welch |
| APTT, mean (range) | 1.06 (0.78–1.88) | 1.07 (0.60–2.09) | 0.81 | Welch |
| PT, mean (range), % | 87.4 (18–116) | 84.8 (42–124) | 0.38 | Welch |
| Initial stroke severity | ||||
| NIHSS score at admission, mean (SD) | 7.14 (±7.62) | 10.2 (±9.72) | 0.071 | Welch |
TIA, transient ischemic attack; ARA-2, angiotensin II receptor antagonists; ACE, angiotensin-converting enzyme; CRP, C-reactive protein; APTT, activated partial thromboplastin time; PT, prothrombin time; NIHSS: National Institutes of Health Stroke Scale; TE, thrombotic event; COVID-, COVID-negative; COVID+, COVID- positive.